BofA reinstated coverage of Bristol Myers (BMY) with a Neutral rating and $63 price target The stock is up 47% since July 1, but at these levels further meaningful upside “seems more difficult,” the analyst tells investors while reinstating coverage of 11 large-cap U.S. pharma and biotech stocks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bausch Health appoints Jonathan Sadeh as CMO, head of R&D
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Bristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy
- Bristol Myers receives positive CHMP opinion for repotrectinib
- Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story